Trials / No Longer Available
No Longer AvailableNCT05086094
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
Intermediate-Size Patient Population Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Biohaven Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this expanded access program is to provide access to the investigational drug verdiperstat in patients with Multiple System Atrophy (MSA). Expanded access allows patients with a serious or a life-threatening disease or condition access to an investigational drug when no satisfactory approved treatment options are available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BHV3241, verdiperstat | BHV3241/Verdiperstat 600mg BID |
Timeline
- First posted
- 2021-10-20
- Last updated
- 2022-10-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05086094. Inclusion in this directory is not an endorsement.